OASIS potentially represents a paradigm shift in solid tumour treatment
• Cohort Review Committee (CRC) observed no safety issues in the onCARlytics
monotherapy lead-in study and recommended opening of the combination arm of
the study
• Ovarian, breast and melanoma patients treated to date in the monotherapy arm
Thats what we needed. NO SAFETY ISSUES! We know CF34 kills cancer in humans. Now we know the ONCARLYTICS version is safe. That’s cleared away any hurdles that concerned me.
Now it’s time to start paradigm shifting a a big way.
Seagen’s $43 bn takeover. IMU says “hold me beer”
Ann: Phase 1 onCARlytics Trial Advances to Combination Arm, page-10
-
- There are more pages in this discussion • 138 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.7¢ |
Change
0.003(5.56%) |
Mkt cap ! $417.2M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.8¢ | 5.2¢ | $2.499M | 45.00M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1921794 | 5.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 1368288 | 7 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMU (ASX) Chart |